A multicenter, prospective phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to anti-EGFR agents (HGCSG1801): Updated analyses. This is an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results